Patents by Inventor John M. Yanni

John M. Yanni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100081646
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: August 19, 2009
    Publication date: April 1, 2010
    Applicant: KALYPSYS, INC.
    Inventors: Steven P. Govek, Clay Beauregard, Daniel A. Gamache, Mark R. Hellberg, Stewart A. Noble, Andrew K. Shiau, David J. Thomas, John M. Yanni
  • Publication number: 20100063047
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Application
    Filed: September 10, 2009
    Publication date: March 11, 2010
    Applicants: KALYPSYS, INC., ALCON RESEARCH, LTD
    Inventors: Allen J. Borchardt, Clay Beauregard, Robert L. Davis, Daniel A. Gamache, John M. Yanni
  • Patent number: 7671070
    Abstract: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: March 2, 2010
    Assignee: Alcon, Inc.
    Inventors: Gerald Cagle, Robert L. Abshire, David W. Stroman, John M. Yanni
  • Publication number: 20100048522
    Abstract: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
    Type: Application
    Filed: November 3, 2009
    Publication date: February 25, 2010
    Applicant: ALCON, INC.
    Inventors: Gerald Cagle, Robert L. Abshire, David W. Stroman, John M. Yanni
  • Publication number: 20090324507
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Application
    Filed: April 13, 2007
    Publication date: December 31, 2009
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • Publication number: 20090274631
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Application
    Filed: April 10, 2007
    Publication date: November 5, 2009
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • Publication number: 20090182035
    Abstract: Disclosed are methods of treating allergic conjunctivitis and non-infectious rhinitis in a subject that involve topically administering to the subject a composition comprising olopatadine and cilomilast.
    Type: Application
    Filed: March 18, 2009
    Publication date: July 16, 2009
    Applicant: Alcon Research, Ltd.
    Inventors: John M. Yanni, Daniel A. Gamache, Steven T. Miller, Clay Beauregard
  • Publication number: 20090131449
    Abstract: Methods of treating symptoms of dry eye by administering inhibitors of transient receptor potential cation channel, subfamily V, member 1 (TRPV1) are disclosed. Methods of preventing or alleviating ocular pain by administering TRPV1 inhibitors are also disclosed.
    Type: Application
    Filed: November 18, 2008
    Publication date: May 21, 2009
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Daniel A. Gamache
  • Publication number: 20090098136
    Abstract: Methods of treating dry eye by administering inhibitors of tumor necrosis factor ? (TNF?) are disclosed.
    Type: Application
    Filed: October 15, 2008
    Publication date: April 16, 2009
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Daniel A. Gamache, John M. Yanni, Martin B. Wax
  • Publication number: 20080254029
    Abstract: Disclosed are methods of treating allergic conjunctivitis and allergic rhinitis in a subject that involve topically administering to the subject a composition comprising a pharmaceutically effective amount of an H1 antagonist and an anti-TNF? compound.
    Type: Application
    Filed: April 10, 2008
    Publication date: October 16, 2008
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Daniel A. Gamache, Steven T. Miller, Clay Beauregard
  • Publication number: 20080139531
    Abstract: Disclosed are methods of treating a wound in a subject that involve administering to the subject a pharmaceutically effective amount of a composition that includes one or more human connective tissue mast cell stabilizers, wherein administration of the composition results in treatment of the wound. In particular embodiments, the wound is an ophthalmic or dermal wound, such as a corneal epithelial defect, a conjunctival wound, or dermal abrasion. Administration, for example, may be by topical application of the composition to the ocular surface or skin. Exemplary mast cell stabilizers include olopatadine, variants of olopatadine, alcaftidine, derivatives of alcaftidine, dihydropyridines, and spleen tyrosine kinase inhibitors.
    Type: Application
    Filed: November 29, 2007
    Publication date: June 12, 2008
    Applicant: ALCON MANUFACTURING LTD.
    Inventors: John M. Yanni, Daniel A. Gamache, Steven T. Miller
  • Patent number: 6872382
    Abstract: Selective PDE-IV inhibitors are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: March 29, 2005
    Assignee: Alcon, Inc.
    Inventors: Daniel A. Gamache, John M. Yanni
  • Publication number: 20040248794
    Abstract: The present invention provides compositions comprising the 15-lipoxygenase-1 (15-LO-1) or 15-lipoxyngenase-2 (15-LO-2) gene such that 15-LO-1 or 15-LO-2 protein expression is replaced or replenished in the ocular surface epithelium of postmenopausal women suffering from dry eye. Thus, methods for treatment of dry eye in postmenopausal women are further provided.
    Type: Application
    Filed: October 17, 2003
    Publication date: December 9, 2004
    Inventors: John M. Yanni, Daniel A. Gamache, Steven T. Miller
  • Publication number: 20040242638
    Abstract: Compositions and methods for treating rhinitis with H1 antagonists/antiallergics and safe steroids are disclosed.
    Type: Application
    Filed: June 2, 2004
    Publication date: December 2, 2004
    Inventors: John M Yanni, Daniel A Gamache
  • Publication number: 20040162315
    Abstract: The present invention provides methods for the treatment of conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma.
    Type: Application
    Filed: February 10, 2004
    Publication date: August 19, 2004
    Inventors: Mark R. Hellberg, Iok-Hou Pang, John M. Yanni
  • Publication number: 20040132773
    Abstract: The use of 3-benzolphenylacetic acids and derivatives, including nepafenac, to treat neurodegenerative retinal disorders is disclosed.
    Type: Application
    Filed: February 14, 2003
    Publication date: July 8, 2004
    Inventors: Daniel A Gamache, Gustav Graff, John M Yanni, Michael A Kapin
  • Publication number: 20040132704
    Abstract: Topical ophthalmic compositions and methods for treating dry eye are described. The compositions and methods of the invention are based on the finding that the oculosurface selective properties of the glucocorticoid rimexolone make this anti-inflammatory agent particularly well-suited for treating dry eye. As a result of the limited ability of rimexolone to penetrate the cornea, a high portion of the drug remains on the surface of the eye, which is the primary locus of the inflammatory conditions associated with dry eye. This enables a very low concentration of drug to be utilized, which in turn reduces the potential for elevations of intraocular pressure and cataract formation.
    Type: Application
    Filed: December 18, 2003
    Publication date: July 8, 2004
    Inventors: John M. Yanni, Daniel A. Gamache, Steven T. Miller, Ernesto J. Castillo
  • Patent number: 6740664
    Abstract: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues. The compositions and methods of the invention are particularly useful in the treatment of acute otitis externa infections and ophthalmic infections attributable to one or both of two newly identified Microbacterium species, Microbacterium otitidis and Microbacterium alconae.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: May 25, 2004
    Assignee: Alcon, Inc.
    Inventors: Gerald Cagle, Robert L. Abshire, David W. Stroman, Celeste H. McLean, Linda L. Clark, John M. Yanni
  • Publication number: 20040097512
    Abstract: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
    Type: Application
    Filed: November 17, 2003
    Publication date: May 20, 2004
    Inventors: Gerald Cagle, Robert L. Abshire, David W. Stroman, John M. Yanni
  • Publication number: 20040097486
    Abstract: Compositions and methods for treating VKC, GPC, AKC and allergic conjunctivitis with H1 antagonists and ocularly safe steroids are disclosed.
    Type: Application
    Filed: November 7, 2003
    Publication date: May 20, 2004
    Inventor: John M. Yanni